A Phase 2a Multicenter, Randomized, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CBT-001 Ophthalmic Solution in Patients With Primary or Recurrent Pterygium

Trial Profile

A Phase 2a Multicenter, Randomized, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CBT-001 Ophthalmic Solution in Patients With Primary or Recurrent Pterygium

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2018

At a glance

  • Drugs CBT 001 (Primary)
  • Indications Pterygium
  • Focus Therapeutic Use
  • Sponsors Cloudbreak therapeutics
  • Most Recent Events

    • 17 Jul 2018 Planned primary completion date changed from 26 May 2018 to 30 Sep 2018.
    • 26 Apr 2018 Planned End Date changed from 1 Feb 2018 to 30 Sep 2018.
    • 26 Apr 2018 Planned primary completion date changed from 1 Feb 2018 to 26 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top